|
1
|
Basu B, Sirohi B and Corrie P: Systemic
therapy for neuroendocrine tumours of gastroenteropancreatic
origin. Endocr Relat Cancer. 17:R75–R90. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Nagtegaal ID, Odze RD, Klimstra D, Paradis
V, Rugge M, Schirmacher P, Washington KM, Carneiro F and Cree IA;
WHO Classification of Tumours Editorial Board, : The 2019 WHO
classification of tumours of the digestive system. Histopathology.
76:182–188. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dasari A, Shen C, Halperin D, Zhao B, Zhou
S, Xu Y, Shih T and Yao JC: Trends in the incidence, prevalence,
and survival outcomes in patients with neuroendocrine tumors in the
United States. JAMA Onco. l3:1335–1342. 2017. View Article : Google Scholar
|
|
4
|
Iwasa S, Morizane C, Okusaka T, Ueno H,
Ikeda M, Kondo S, Tanaka T, Nakachi K, Mitsunaga S, Kojima Y, et
al: Cisplatin and etoposide as first-line chemotherapy for poorly
differentiated neuroendocrine carcinoma of the hepatobiliary tract
and pancreas. Jpn J Clin Oncol. l40:313–318. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mosalem O, Sonbol MB, Halfdanarson TR and
Starr JS: Tyrosine kinase inhibitors and immunotherapy updates in
neuroendocrine neoplasms. Best Pract Res Clin Endocrinol Metab.
37:1017962023. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liao X and Zhang D: The 8th Edition
American Joint Committee on cancer staging for
hepato-pancreato-biliary cancer: A review and update. Arch Pathol
Lab Med. 145:543–553. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ma ZY, Gong YF, Zhuang HK, Zhou ZX, Huang
SZ, Zou YP, Huang BW, Sun ZH, Zhang CZ, Tang YQ and Hou BH:
Pancreatic neuroendocrine tumors: A review of serum biomarkers,
staging, and management. World J Gastroenterol. 26:2305–2322. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cheng Y, Wang Q, Li K, Shi J, Liu Y, Wu L,
Han B, Chen G, He J, Wang J, et al: Anlotinib vs placebo as third-
or further-line treatment for patients with small cell lung cancer:
A randomised, double-blind, placebo-controlled phase 2 study. Br J
Cancer. 125:366–371. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Xie C, Wan X, Quan H, Zheng M, Fu L, Li Y
and Lou L: Preclinical characterization of anlotinib, a highly
potent and selective vascular endothelial growth factor receptor-2
inhibitor. Cancer Sci. 109:1207–1219. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Taurin S, Yang CH, Reyes M, Cho S, Coombs
DM, Jarboe EA, Werner TL, Peterson CM and Janát-Amsbury MM:
Endometrial cancers harboring mutated fibroblast growth factor
receptor 2 protein are successfully treated with a new small
tyrosine kinase inhibitor in an orthotopic mouse model. Int J
Gynecol Cancer. 28:152–160. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lin B, Song X, Yang D, Bai D, Yao Y and Lu
N: Anlotinib inhibits angiogenesis via suppressing the activation
of VEGFR2, PDGFRβ and FGFR1. Gene. 654:77–86. 2018. View Article : Google Scholar : PubMed/NCBI
|
